135 related articles for article (PubMed ID: 36908010)
1. CRISPR/Cas9 Screen in Gastric Cancer Patient-Derived Organoids Reveals KDM1A-NDRG1 Axis as a Targetable Vulnerability.
Mircetic J; Camgöz A; Abohawya M; Ding L; Dietzel J; Tobar SG; Paszkowski-Rogacz M; Seidlitz T; Schmäche T; Mehnert MC; Sidorova O; Weitz J; Buchholz F; Stange DE
Small Methods; 2023 Jun; 7(6):e2201605. PubMed ID: 36908010
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-329 inhibits cell proliferation and tumor growth while facilitates apoptosis via negative regulation of KDM1A in gastric cancer.
Cai L; Chen Q; Fang S; Lian M; Cai M
J Cell Biochem; 2018 Apr; 119(4):3338-3351. PubMed ID: 29130516
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
Venkata PP; Jayamohan S; He Y; Alejo S; Johnson JD; Palacios BE; Pratap UP; Chen Y; Liu Z; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Weintraub ST; Palakurthi S; Valente PT; Tekmal RR; Kost ER; Vadlamudi RK; Sareddy GR
Cancer Lett; 2023 Oct; 575():216383. PubMed ID: 37714256
[TBL] [Abstract][Full Text] [Related]
4. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
5. Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis.
Nanki K; Toshimitsu K; Takano A; Fujii M; Shimokawa M; Ohta Y; Matano M; Seino T; Nishikori S; Ishikawa K; Kawasaki K; Togasaki K; Takahashi S; Sukawa Y; Ishida H; Sugimoto S; Kawakubo H; Kim J; Kitagawa Y; Sekine S; Koo BK; Kanai T; Sato T
Cell; 2018 Aug; 174(4):856-869.e17. PubMed ID: 30096312
[TBL] [Abstract][Full Text] [Related]
6. A protocol for efficient CRISPR-Cas9-mediated knock-in in colorectal cancer patient-derived organoids.
Okamoto T; Natsume Y; Yamanaka H; Fukuda M; Yao R
STAR Protoc; 2021 Dec; 2(4):100780. PubMed ID: 34585151
[TBL] [Abstract][Full Text] [Related]
7. KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway.
Zhang W; Ruan X; Li Y; Zhi J; Hu L; Hou X; Shi X; Wang X; Wang J; Ma W; Gu P; Zheng X; Gao M
Theranostics; 2022; 12(4):1500-1517. PubMed ID: 35198054
[No Abstract] [Full Text] [Related]
8. CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes.
Takeda H; Kataoka S; Nakayama M; Ali MAE; Oshima H; Yamamoto D; Park JW; Takegami Y; An T; Jenkins NA; Copeland NG; Oshima M
Proc Natl Acad Sci U S A; 2019 Jul; 116(31):15635-15644. PubMed ID: 31300537
[TBL] [Abstract][Full Text] [Related]
9. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
10. The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.
Pajtler KW; Weingarten C; Thor T; Künkele A; Heukamp LC; Büttner R; Suzuki T; Miyata N; Grotzer M; Rieb A; Sprüssel A; Eggert A; Schramm A; Schulte JH
Acta Neuropathol Commun; 2013 May; 1():19. PubMed ID: 24252778
[TBL] [Abstract][Full Text] [Related]
11. Modeling Wnt signaling by CRISPR-Cas9 genome editing recapitulates neoplasia in human Barrett epithelial organoids.
Liu X; Cheng Y; Abraham JM; Wang Z; Wang Z; Ke X; Yan R; Shin EJ; Ngamruengphong S; Khashab MA; Zhang G; McNamara G; Ewald AJ; Lin D; Liu Z; Meltzer SJ
Cancer Lett; 2018 Nov; 436():109-118. PubMed ID: 30144514
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.
McGrath JP; Williamson KE; Balasubramanian S; Odate S; Arora S; Hatton C; Edwards TM; O'Brien T; Magnuson S; Stokoe D; Daniels DL; Bryant BM; Trojer P
Cancer Res; 2016 Apr; 76(7):1975-88. PubMed ID: 26837761
[TBL] [Abstract][Full Text] [Related]
13. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of KDM1A suppresses tumour migration and invasion by epigenetically regulating the TIMP1/MMP9 pathway in papillary thyroid cancer.
Zhang W; Sun W; Qin Y; Wu C; He L; Zhang T; Shao L; Zhang H; Zhang P
J Cell Mol Med; 2019 Aug; 23(8):4933-4944. PubMed ID: 31211500
[TBL] [Abstract][Full Text] [Related]
15. KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.
Venkata PP; Chen Y; Alejo S; He Y; Palacios BE; Loeffel I; Liu J; Pratap UP; Gray G; Achuthan Pillai SM; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Palakurthi S; Tekmal RR; Vadlamudi RK; Kost E; Sareddy GR
Cancer Lett; 2022 Jan; 524():219-231. PubMed ID: 34673129
[TBL] [Abstract][Full Text] [Related]
16. KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Zhou M; Venkata PP; Viswanadhapalli S; Palacios B; Alejo S; Chen Y; He Y; Pratap UP; Liu J; Zou Y; Lai Z; Suzuki T; Brenner AJ; Tekmal RR; Vadlamudi RK; Sareddy GR
Breast Cancer Res Treat; 2021 Jan; 185(2):343-357. PubMed ID: 33057995
[TBL] [Abstract][Full Text] [Related]
17. Lysine demethylase KDM1A promotes cell growth via FKBP8-BCL2 axis in hepatocellular carcinoma.
Lv S; Zhao X; Zhang E; Yan Y; Ma X; Li N; Zou Q; Sun L; Song T
J Biol Chem; 2022 Sep; 298(9):102374. PubMed ID: 35970393
[TBL] [Abstract][Full Text] [Related]
18. The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent.
Brenner C; Luciani J; Bizet M; Ndlovu M; Josseaux E; Dedeurwaerder S; Calonne E; Putmans P; Cartron PF; Defrance M; Fuks F; Deplus R
Oncotarget; 2016 Sep; 7(37):58939-58952. PubMed ID: 27449289
[TBL] [Abstract][Full Text] [Related]
19. A CRISPR/Cas9-Engineered
Lo YH; Kolahi KS; Du Y; Chang CY; Krokhotin A; Nair A; Sobba WD; Karlsson K; Jones SJ; Longacre TA; Mah AT; Tercan B; Sockell A; Xu H; Seoane JA; Chen J; Shmulevich I; Weissman JS; Curtis C; Califano A; Fu H; Crabtree GR; Kuo CJ
Cancer Discov; 2021 Jun; 11(6):1562-1581. PubMed ID: 33451982
[TBL] [Abstract][Full Text] [Related]
20. Germline Lysine-Specific Demethylase 1 (
Wei X; Calvo-Vidal MN; Chen S; Wu G; Revuelta MV; Sun J; Zhang J; Walsh MF; Nichols KE; Joseph V; Snyder C; Vachon CM; McKay JD; Wang SP; Jayabalan DS; Jacobs LM; Becirovic D; Waller RG; Artomov M; Viale A; Patel J; Phillip J; Chen-Kiang S; Curtin K; Salama M; Atanackovic D; Niesvizky R; Landgren O; Slager SL; Godley LA; Churpek J; Garber JE; Anderson KC; Daly MJ; Roeder RG; Dumontet C; Lynch HT; Mullighan CG; Camp NJ; Offit K; Klein RJ; Yu H; Cerchietti L; Lipkin SM
Cancer Res; 2018 May; 78(10):2747-2759. PubMed ID: 29559475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
